Business Description
Cardiol Therapeutics is a Canadian clinical-stage company focused on developing treatments for serious heart conditions, including myocarditis, pericarditis, and heart failure. Its main drug candidate, CardiolRx, is currently being tested in a large international clinical trial to assess how well it works and how safe it is. The company is also working on an injectable treatment called CRD-38, which is in early-stage research for patients with heart failure. Founded in 2017 and based in Oakville, Ontario, Cardiol operates under a licensing agreement that supports its drug development efforts.
